Frisiras Angelos, Giannas Emmanuel, Bobotis Stergios, Kanella Ilektra, Arjomandi Rad Arian, Viviano Alessandro, Spiliopoulos Kyriakos, Magouliotis Dimitrios E, Athanasiou Thanos
Faculty of Medicine, Imperial College London, Charing Cross Hospital, London W6 8RF, UK.
Medical Sciences Division, University of Oxford, Oxford OX1 3AZ, UK.
J Clin Med. 2023 Jul 29;12(15):5001. doi: 10.3390/jcm12155001.
Due to an ever-increasing ageing population and limited available data around the use of thoracic endovascular aortic repair (TEVAR) in elderly patients, investigating its efficacy and safety in this age cohort is of vital importance. We thus reviewed the existing literature on this topic to assess the feasibility of TEVAR in elderly patients with severe thoracic aortic pathologies.
We identified all original research studies that assessed TEVAR in elderly patients published up to 2023. Morbidity, as assessed by neurological and respiratory complications, endoleaks, and length of stay, was the primary endpoint. Short-term mortality and long-term survival were the secondary endpoints. The Mantel-Haenszel random and fixed effects methods were used to calculate the odds ratios for each outcome. Further sensitivity and subgroup analyses were performed to validate the outcomes.
Twelve original studies that evaluated elective TEVAR outcomes in elderly patients were identified. Seven studies directly compared the use of TEVAR between an older and a younger patient group. Apart from a shorter hospital stay in older patients, no statistically significant difference between the morbidity outcomes of the two different cohorts was found. Short-term mortality and long-term survival results favoured the younger population.
The present meta-analysis indicates that, due to a safe perioperative morbidity profile, TEVAR should not be contraindicated in patients based purely on old age. Further research using large patient registries to validate our findings in elderly patients with specific aortic pathologies and both elective and emergency procedures is necessary.
鉴于老年人口不断增加,且关于老年患者使用胸主动脉腔内修复术(TEVAR)的可用数据有限,研究其在该年龄组中的疗效和安全性至关重要。因此,我们回顾了关于这一主题的现有文献,以评估TEVAR在患有严重胸主动脉病变的老年患者中的可行性。
我们检索了截至2023年发表的所有评估老年患者TEVAR的原始研究。以神经和呼吸并发症、内漏及住院时间评估的发病率为主要终点。短期死亡率和长期生存率为次要终点。采用Mantel-Haenszel随机和固定效应方法计算各结局的比值比。进行了进一步的敏感性和亚组分析以验证结果。
确定了12项评估老年患者择期TEVAR结局的原始研究。7项研究直接比较了老年患者组和年轻患者组使用TEVAR的情况。除老年患者住院时间较短外,未发现两个不同队列的发病结局有统计学显著差异。短期死亡率和长期生存结果有利于年轻人群。
本荟萃分析表明,由于围手术期发病率安全,不应单纯基于年龄而将TEVAR列为患者的禁忌。有必要使用大型患者登记数据库进行进一步研究,以验证我们在患有特定主动脉病变的老年患者以及择期和急诊手术中的研究结果。